IDXX | Ticker Profile - Titan Protect

IDXX

Idexx Laboratories

Health Care · Health Care Equipment · US

$562.16

Data: 2026-05-15

✓ ETHICAL PASS

STRONG MOAT

HIGH

Data Confidence: 100.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$41.8B

Total market value of the company

Trailing P/E

38.96

Expensive — high growth expected

Forward P/E

32.06

Based on estimated future earnings — lower means cheaper

Rev Growth

+14.3%

Year-over-year revenue change

Profit Margin

24.6%

How much profit the company keeps from each dollar of revenue

ROE

72.9%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$709.14

+26% from current price — median analyst estimate

Recommendation

BUY

Consensus view from 14 analysts covering this stock

About Idexx Laboratories

IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally. It operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. The company offers point-of-care diagnostic solutions, blood and urine chemistry, hematology, immunoassay, urinalysis, cytology/morphology, and coagulation analyzers; and SNAP rapid assays test kits. It also provides commercial reference laboratory diagnostic and consulting services to veterinarians; veterinary consultation, telemedicine, and advisory services, including radiology, dental radiography, cardiology, internal medicine, and ultrasound consulting; Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, Quanti-Tray products, and Tecta system instruments; UV Viewer Plus, a UV light cabinet which aids in the visual interpretation of fluorescent-based water tests; and veterinary software and services for independent veterinary clinics and corporate groups. In addition, the company offers diagnostic tests, services, and related instrumentation to manage the health status of livestock and poultry; human medical diagnostic products and services; and VetConnect PLUS, a cloud-based technology that enables veterinarians to access and analyze patients, as well as operates VetLab Station. It markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.

https://www.idexx.com

Country: United States Employees: 11,000 Industry: Diagnostics & Research

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

29.1% PASS

Debt must be below 33% of total assets

Cash Ratio

1.7% PASS

Interest-bearing cash below 33% of assets

Receivables

21.9% PASS

Receivables below 49% of assets

Revenue Purity

0.1% PASS

Non-compliant revenue below 5% — any excess requires purification

Valuation

Fair Value Est.

$236.18

What our model estimates this business is worth per share

Margin of Safety

-138.0%

Trading above fair value — no margin of safety

Rating

OVERVALUED

Overall assessment combining ethics, valuation, and quality

Percentile

90.1th

Ranks in the top 10% of our 13,571 screened universe

Ethical Score

82.7

Valuation Score

30.5

Quality Score

88.3

Combined

63.7

Trading at $529, 124% above fair value of $236. Strong competitive moat. 25% profit margins. Passes all ethical screens. Ranks better than 69% of screened stocks.

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

DISTRIBUTION

Smart money appears to be selling into strength — caution

Sharpe Ratio

0.309

Positive but modest risk-adjusted returns

Kelly Fraction

0.0318

Modest edge detected — smaller position warranted

Calmar Ratio

0.162

Drawdown risk outweighs the returns — higher risk profile

Annual Return

5.0%

Historical annualised return based on price data

Max Drawdown

-31.0%

Largest peak-to-trough decline — the worst it has been

HMM State

BEAR

Statistical model detects bearish conditions

Days in State

119

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

1.57

Significantly more volatile than the market

52W High

$769.98

27% below the year high

52W Low

$496.61

13% above the year low

Avg Volume

547,311

Average daily shares traded — higher means easier to buy and sell

Short Ratio

3.8

Days it would take all short sellers to cover — higher means more crowded

Short % Float

3.0%

Low short interest — limited bearish positioning

Div Yield

0.0%

Annual dividend as a percentage of the share price

EPS (TTM)

$13.61

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

0.71

Moderate leverage — manageable

Current Ratio

1.12

Adequate but worth monitoring

Quick Ratio

0.69

Like current ratio but excludes inventory — stricter test

Gross Margin

62.1%

Revenue left after cost of goods — higher means pricing power

Operating Margin

31.8%

Profit from core operations before interest and tax

Free Cash Flow

$787M

Positive — the business generates more cash than it spends

Revenue (TTM)

$4.4B

Total revenue over the last 12 months

Net Income

$1.1B

Profitable — the bottom line is positive

Analyst Coverage

Analysts

Target High

$805.00

Target Median

$709.14

Target Low

$470.00

Recent Insider Activity

SEC Form 4 filings — what company insiders are buying and selling

55

NEUTRAL

Mixed insider activity. 0 purchases and 0 sales in the last 90 days — no clear directional signal. Politicians have been buying this name.

Date	Insider	Title	Shares	Value
2026-05-07	SZOSTAK MARGARET ANNE	Director	257	—
2026-05-07	JUNIUS DANIEL M	Director	257	—
2026-05-07	VANDEBROEK SOPHIE V	Director	257	—
2026-05-07	KINGSLEY LAWRENCE D	Director	339	—
2026-05-07	HOOLEY JOSEPH L.	Director	158	—
2026-05-07	PEACOCK KAREN	Director	101	—
2026-04-30	HOOLEY JOSEPH L.	Director	43	$24,114
2026-03-03	HUNT NIMRATA K	Officer	1,758	$1,115,577
2026-03-03	UNDERBERG SHARON E	General Counsel	197	$99,589
2026-02-27	MAZELSKY JONATHAN JAY	Chief Executive Officer	23,523	$3,402,551

Source: SEC Form 4 filings via public data. View all insider activity at

Insider Intelligence

Political Trading Activity

Congressional trading disclosures involving this instrument

Date	Politician	Party	Type	Amount
2026-04-13	Ro Khanna	Democrat	Purchase	1K–15K

Source: Congressional disclosure filings. View all political trades at

Insider Intelligence

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-15

Before you go